Specify a stock or a cryptocurrency in the search bar to get a summary
MAIA Biotechnology Inc.
MAIAMAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Address: 444 West Lake Street, Chicago, IL, United States, 60606
Analytics
WallStreet Target Price
12.63 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MAIA
Dividend Analytics MAIA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MAIA
Stock Valuation MAIA
Financials MAIA
Results | 2019 | Dynamics |